Suppr超能文献

沙利度胺联合经动脉化疗栓塞治疗原发性肝细胞癌:一项系统评价与Meta分析

Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.

作者信息

Cao De-Dong, Xu Hui-Lin, Liu Liang, Zheng Yong-Fa, Gao Si-Fa, Xu Xi-Ming, Ge Wei

机构信息

Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China.

Department of Oncology, The Fifth Hospital of WuHan, WuHan, Hubei, China.

出版信息

Oncotarget. 2017 Jul 4;8(27):44976-44993. doi: 10.18632/oncotarget.16689.

Abstract

OBJECTIVE

Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC). This study aims to evaluate the clinical efficacy and safety of thalidomide and TACE in primary HCC.

METHODS

Randomized controlled trials(RCTs) about efficacy and safety of thalidomide combined with TACE for primary HCC were identified from the Cochrane Library, Pubmed, Embase, CNKI, and Wan Fang until August, 2016. The retrieved trials were reviewed and the data were extracted by two reviewers, independently. Combined analyses of survival rates, overall response rate(ORR), disease control rate(DCR), changes of KPS, parameters of cellular immunity and vascular endothelial growth factor(VEGF), and adverse events were performed using RevMan 5.3 software.

RESULTS

A total of 23 RCTs involving 1836 patients were included. The results showed that thalidomide plus TACE was significantly superior in increasing 6-month survival rate(OR=1.79, 95% CI:1.02-3.15, P=0.04), 1-year survival rate(OR=1.76, 95% CI:1.38-2.24, P<0.0001), 1.5-year survival rate(OR=4.72, 95% CI:2.64-8.43, P<0.001), 2-year survival rate(OR=1.78, 95% CI:1.37-2.30, P<0.001), ORR(OR=1.89, 95% CI:1.48-2.42, P<0.0001), DCR(OR=2.62, 95% CI:1.90-3.63, P<0.001), improvement in cellular immunity(MD=0.63, 95% CI:0.45-0.80, P<0.0001), and reduction of VEGF(MD=-119.71, 95% CI:-135.75-103.68, P<0.0001), when compared with TACE group. The incidences of gastrointestinal reactions, myelosuppression, and liver dysfunction were similar between combination group and TACE group(P>0.05). However, compared to TACE, the combination of thalidomide and TACE had a higher incidence of drug rash(OR=6.35, 95% CI:2.75-14.68, P<0.0001).

CONCLUSION

Our findings suggest that thalidomide combined with TACE shows better clinical efficacy and tolerable adverse events in patients with primary HCC when compared with TACE alone.

摘要

目的

经动脉化疗栓塞术(TACE)和沙利度胺已用于治疗原发性肝细胞癌(HCC)。本研究旨在评估沙利度胺联合TACE治疗原发性HCC的临床疗效和安全性。

方法

从Cochrane图书馆、Pubmed、Embase、中国知网和万方数据库中检索截至2016年8月关于沙利度胺联合TACE治疗原发性HCC疗效和安全性的随机对照试验(RCT)。由两名研究者独立对检索到的试验进行评估并提取数据。使用RevMan 5.3软件对生存率、总缓解率(ORR)、疾病控制率(DCR)、KPS评分变化、细胞免疫参数和血管内皮生长因子(VEGF)以及不良事件进行合并分析。

结果

共纳入23项RCT,涉及1836例患者。结果显示,与TACE组相比,沙利度胺联合TACE在提高6个月生存率(OR = 1.79,95%CI:1.02 - 3.15,P = 0.04)、1年生存率(OR = 1.76,95%CI:1.38 - 2.24,P < 0.0001)、1.5年生存率(OR = 4.72,95%CI:2.64 - 8.43,P < 0.001)、2年生存率(OR = 1.78,95%CI:1.37 - 2.30,P < 0.001)、ORR(OR = 1.89,95%CI:1.48 - 2.42,P < 0.0001)、DCR(OR = 2.62,95%CI:1.90 - 3.63,P < 0.001)、改善细胞免疫(MD = 0.63,95%CI:0.45 - 0.80,P < 0.0001)以及降低VEGF(MD = -119.71,95%CI:-135.75 - 103.68,P < 0.0001)方面显著更优。联合组与TACE组的胃肠道反应、骨髓抑制和肝功能障碍发生率相似(P > 0.05)。然而,与TACE相比,沙利度胺联合TACE的皮疹发生率更高(OR = 6.35,95%CI:2.75 - 14.68,P < 0.0001)。

结论

我们的研究结果表明,与单独使用TACE相比,沙利度胺联合TACE治疗原发性HCC患者具有更好的临床疗效和可耐受的不良事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1e4/5546534/d971a70d1de6/oncotarget-08-44976-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验